Lantern Pharma Inc
LTRN
NASDAQ
Biotechnology
$2.65
USD
+0.02 (+0.76%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $34.19M
Volume 165.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-15.91M
TTM
+19.9%
YoY
Operating Cash Flow
$-15.07M
TTM
+21.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.5 | 1.6 | 1.9 | 1.5 | 1.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.8 | 4.7 | 4.3 | 4.2 | 3.4 |
Operating Income | -4.8 | -4.7 | -4.3 | -4.2 | -3.4 |
EBITDA | -4.8 | -4.6 | -4.3 | -4.2 | -3.4 |
Other Income / Expense | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 |
Total Other Income / Expense | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 |
Income Before Income Taxes | -4.5 | -4.3 | -4.2 | -4.1 | -3.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.5 | -4.3 | -4.2 | -4.1 | -3.3 |
Consolidated Net Income / Loss | -4.5 | -4.3 | -4.2 | -4.1 | -3.3 |
Net Income Attributable to Common Shareholders | -4.5 | -4.3 | -4.2 | -4.1 | -3.3 |
Basic EPS | -$0.42 | -$0.40 | -$0.39 | -$0.36 | -$0.30 |
Diluted EPS | -$0.42 | -$0.40 | -$0.39 | -$0.36 | -$0.30 |
Basic Shares Outstanding | 10.8M | 10.8M | 10.8M | 11.2M | 11.3M |
Diluted Shares Outstanding | 10.8M | 10.8M | 10.8M | 11.2M | 11.3M |